164 related articles for article (PubMed ID: 6714290)
1. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
[TBL] [Abstract][Full Text] [Related]
2. Acetylator phenotype and the antihypertensive response to hydralazine.
Jounela AJ; Pasanen M; Mattila MJ
Acta Med Scand; 1975 Apr; 197(4):303-6. PubMed ID: 1136859
[TBL] [Abstract][Full Text] [Related]
3. Hydrallazine and beta-blockade in refractory hypertension with characterization of acetylator phenotype.
Hunyor SN
Aust N Z J Med; 1975 Dec; 5(6):530-6. PubMed ID: 7224
[TBL] [Abstract][Full Text] [Related]
4. Acetylator phenotype in patients with hydralazine-induced lupoid syndrome.
Strandberg I; Boman G; Hassler L; Sjöqvist F
Acta Med Scand; 1976; 200(5):367-71. PubMed ID: 983808
[TBL] [Abstract][Full Text] [Related]
5. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
Clark DW
Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
[TBL] [Abstract][Full Text] [Related]
6. Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital.
Rashid JR; Kofi-Tsepko ; Juma FD
East Afr Med J; 1992 Jul; 69(7):406-8. PubMed ID: 1396201
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
Gonzalez-Fierro A; Vasquez-Bahena D; Taja-Chayeb L; Vidal S; Trejo-Becerril C; Pérez-Cardenas E; de la Cruz-Hernández E; Chávez-Blanco A; Gutiérrez O; Rodriguez D; Fernandez Z; Duenas-González A
Int J Clin Pharmacol Ther; 2011 Aug; 49(8):519-24. PubMed ID: 21781652
[TBL] [Abstract][Full Text] [Related]
8. Hydralazine-induced lupus: is there a toxic metabolic pathway?
Timbrell JA; Facchini V; Harland SJ; Mansilla-Tinoco R
Eur J Clin Pharmacol; 1984; 27(5):555-9. PubMed ID: 6519160
[TBL] [Abstract][Full Text] [Related]
9. Further evidence for an acetylator phenotype difference in the metabolism of hydralazine in man.
Facchini V; Timbrell JA
Br J Clin Pharmacol; 1981 Apr; 11(4):345-51. PubMed ID: 7259927
[TBL] [Abstract][Full Text] [Related]
10. Effect of dose on acetylator phenotype distribution of hydralazine.
Timbrell JA; Harland SJ; Facchini V
Clin Pharmacol Ther; 1981 Mar; 29(3):337-43. PubMed ID: 7471604
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of once daily hydralazine in inadequately controlled hypertension.
Danielson M; Kjellberg J; Ohman P; Wernersson B
Acta Med Scand; 1983; 214(5):373-80. PubMed ID: 6362341
[TBL] [Abstract][Full Text] [Related]
12. Plasma concentration and acetylator phenotype determine response to oral hydralazine.
Shepherd AM; McNay JL; Ludden TM; Lin MS; Musgrave GE
Hypertension; 1981; 3(5):580-5. PubMed ID: 7298112
[TBL] [Abstract][Full Text] [Related]
13. Genotype-Guided Hydralazine Therapy.
Collins KS; Raviele ALJ; Elchynski AL; Woodcock AM; Zhao Y; Cooper-DeHoff RM; Eadon MT
Am J Nephrol; 2020; 51(10):764-776. PubMed ID: 32927458
[TBL] [Abstract][Full Text] [Related]
14. Polymorphic acetylation of hydralazine.
Timbrell JA; Harland SJ; Facchini V
Clin Pharmacol Ther; 1980 Sep; 28(3):350-5. PubMed ID: 7408395
[TBL] [Abstract][Full Text] [Related]
15. [Direct and indirect determination of an acetylator phenotype in patients during treatment with hydralazine].
McNair A; Kristensen MB; Angelo HR; Christensen JM
Ugeskr Laeger; 1981 Jun; 143(27):1696-9. PubMed ID: 7292741
[No Abstract] [Full Text] [Related]
16. Dihydralazine therapy and acetylator phenotype.
Iisalo E; Laine T; Lehtonen A; Sellman R
Int J Clin Pharmacol Biopharm; 1979 Mar; 17(3):119-24. PubMed ID: 429082
[TBL] [Abstract][Full Text] [Related]
17. Immunologic effects of hydralazine in hypertensive patients.
Litwin A; Adams LE; Zimmer H; Hess EV
Arthritis Rheum; 1981 Aug; 24(8):1074-8. PubMed ID: 6974554
[TBL] [Abstract][Full Text] [Related]
18. Hydralazine once daily in hypertension.
Silas JH; Ramsay LE; Freestone S
Br Med J (Clin Res Ed); 1982 May; 284(6329):1602-4. PubMed ID: 6805621
[TBL] [Abstract][Full Text] [Related]
19. Determinants of response to intravenous hydralazine in hypertension.
Shepherd A; Lin MS; McNay J; Ludden T; Musgrave G
Clin Pharmacol Ther; 1981 Dec; 30(6):773-81. PubMed ID: 7307426
[TBL] [Abstract][Full Text] [Related]
20. Endralazine, a new peripheral vasodilator: absence of effect of acetylator status on antihypertensive effect.
Holmes DG; Bogers WA; Wideroe TE; Huunan-Seppala A; Wideroe B
Lancet; 1983 Mar; 1(8326 Pt 1):670-1. PubMed ID: 6132036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
